INmune Bio, Inc. INMB
2.03
0.03
1.50%
as of 25 Sep
- Market cap
- $55.5M
- P/E
- 0.0×
Follow INMB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(155.77%) | (165.16%) | (168.78%) | (74.82%) | |
| (115.83%) | (127.75%) | (130.78%) | (57.08%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (646.94%) | |
Return on Tangible Assets |
(206.22%) | (204.82%) | (226.87%) | (96.06%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.19) | (0.95) | (0.72) | (0.61) | |
Free Cash Flow |
(31.55) | (23.62) | (19.16) | (16.43) | |
Capital Expenditures |
(0.90) | (1.04) | — | (1.47) | |
| Other line items | |||||
Cash ROIC |
(57.71%) | (46.78%) | (46.75%) | (38.59%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.61 | 0.49 | 0.46 | 0.81 | |
Depreciation/Fixed assets |
0.08 | 0.11 | 0.16 | 0.16 | |
Capex/Depreciation |
(12.32) | (9.92) | 0.00 | (7.29) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.15) | (0.91) | (0.72) | (0.56) | |
Capex per Share |
(0.03) | (0.04) | 0.00 | (0.06) | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates